Amarin Corp Plcuk (AMRN) Cash from Operations (2010 - 2026)
Amarin Corp Plcuk (AMRN) posted quarterly Cash from Operations of 6388000.0 for Q1 2026, up 151.27% YoY from 2542263.21 in Q1 2025, and down 58.19% sequentially from 15278000.0 in Q4 2025.
Amarin Corp Plcuk (AMRN) Cash from Operations (2010 - 2026) Analysis & Trends
Amarin Corp Plcuk has disclosed Cash from Operations across 17 years of filings, most recently posting 6388000.0 for Q1 2026.
- In Q1 2026, Cash from Operations rose 151.27% year-over-year to 6388000.0; the TTM figure through Mar 2026 stood at 25575000.0 (up 182.83% YoY), while the FY2025 annual figure was 6728000.0, up 121.69% from the prior year.
- Cash from Operations fell to 6388000.0 in Q1 2026, from 15278000.0 in the prior quarter.
- Over the last five years, Cash from Operations for AMRN reached as high as 16606000.0 in Q2 2025 and fell as low as 98847000.0 in Q1 2022.
- The 5-year median for Cash from Operations is 2749000.0 (2024), against an average of 11242117.65.
- Annual changes were most pronounced in 2024 — Cash from Operations tumbled 1963.57% — and 2025, when it soared 704.07%.
- A 5-year view of Cash from Operations shows it stood at 1552000.0 in 2022, then tumbled by 141.56% to 645000.0 in 2023, then plunged by 1963.57% to 13310000.0 in 2024, then jumped by 214.79% to 15278000.0 in 2025, then slumped by 58.19% to 6388000.0 in 2026.
- According to Business Quant data, Cash from Operations over the past three periods registered 6388000.0, 15278000.0, and 12697000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 5.33 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 2.51 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 3.83 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | - |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 3.92 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 2.19 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 2.54 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 2.62 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Amarin Corp Plcuk | 5.17 Bn | 5.00 Bn | 17.77 Mn | 6.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.39 Mn |
| Mar 31, 2026 | 6.39 Mn |
| Dec 31, 2025 | 15.28 Mn |
| Dec 31, 2025 | 15.28 Mn |
| Sep 30, 2025 | -12.70 Mn |
| Sep 30, 2025 | -12.70 Mn |
| Jun 30, 2025 | 16.61 Mn |
| Jun 30, 2025 | 16.61 Mn |
| Mar 31, 2025 | -12.46 Mn |
| Mar 31, 2025 | -12.46 Mn |
| Dec 31, 2024 | -13.31 Mn |
| Dec 31, 2024 | -13.31 Mn |
| Sep 30, 2024 | -2.36 Mn |
| Sep 30, 2024 | -2.36 Mn |
| Jun 30, 2024 | -2.75 Mn |
| Jun 30, 2024 | -2.75 Mn |
| Mar 31, 2024 | -12.60 Mn |
| Mar 31, 2024 | -12.60 Mn |
| Dec 31, 2023 | -645,000.00 |
| Dec 31, 2023 | -645,000.00 |